What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBA
Prime Medicine
Prime editing company developing genetic therapies for inherited diseases.
Prime Medicine is known for prime editing company developing genetic therapies for inherited diseases. It is based in Cambridge, MA, USA, is at the Public stage, and sits in our Pharma & Drug Discovery category.
What they do
Prime Medicine is advancing PM647, an investigational in vivo prime-editing therapy for alpha-1 antitrypsin deficiency. The FDA cleared its investigational new drug application in September 2026, allowing a US clinical study of the approach targeting the PiZZ genotype. Clinical efficacy remains to be established.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Prime editing
- Product type
- Platform software
- Stage
- Public
- Headquarters
- Cambridge, MA, USA
- Region
- North America
- Founded
- 2019
- Total funding
- Undisclosed
Also in Pharma & Drug Discovery
More in Pharma & Drug Discovery: Pharma & Drug Discovery startups/HealthTech startup database
Related on The Signal
Dr. Dereck Mush, MD, MBA
Top 25 Cardiologists to Follow on LinkedIn in 2026
Dr. Dereck Mush, MD, MBA
The $1 Billion Bet on Pre-Symptomatic Medicine: Who Will Own the Longitudinal Baseline?
Dr. Dereck Mush, MD, MBA
Beyond Paralysis: What Neuralink's Stroke Arm Says About the Brain-Computer Interface Market
Dr. Dereck Mush, MD, MBA